SillaJen Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
49
- Stock Symbol
-
215600
- Investments
-
3
- Share Price
-
$1.42
- (As of Friday Closing)
SillaJen General Information
Description
SillaJen Inc is a Korean based biotechnology company focused on engineering and developing cancer treatment cells. The company along with its subsidiary SillaJen Biotherapeutics, Inc offers Pexa-Vec, an oncolytic virus with antibodies, and improved survival in a randomized trial to cure cancer; and JX929, an engineered vaccinia virus strain that acts on cancer cells by viral attack and subsequent cancer cell oncolysis. SillaJen operates its business activities in Korea and United States.
Contact Information
Website
www.sillajen.comCorporate Office
- 3rd Floor, 106 Cheonggyecheon-ro, Jung-gu
- Seoul, 04542
- South Korea
Corporate Office
- 3rd Floor, 106 Cheonggyecheon-ro, Jung-gu
- Seoul, 04542
- South Korea
SillaJen Stock Performance
As of 13-Nov-2026, SillaJen’s stock price is $1.42. Its current market cap is $197M with 139M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.42 | $1.43 | $1.22 - $3.77 | $197M | 139M | 1.61M | -$0.12 |
SillaJen Financials Summary
As of 30-Jun-2026, SillaJen has a trailing 12-month revenue of $7.42M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 160,080 | 278,707 | 149,761 | 443,171 |
| Revenue | 7,422 | 6,482 | 2,878 | 3,013 |
| EBITDA | (17,707) | (17,870) | (19,789) | (15,330) |
| Net Income | (16,613) | (16,998) | (19,441) | (15,579) |
| Total Assets | 69,566 | 81,119 | 101,167 | 59,530 |
| Total Debt | 908 | 1,573 | 7,257 | 7,524 |
SillaJen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SillaJen Comparisons
Industry
Financing
Details
SillaJen Competitors (68)
One of SillaJen’s 68 competitors is Iovance Biotherapeutics, a Corporation company based in San Carlos, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| NextCure | Formerly VC-backed | Beltsville, MD | ||||
| Marker Therapeutics | Formerly VC-backed | Houston, TX | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA |
SillaJen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
SillaJen Patents
SillaJen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023338427-A1 | Novel use of oncolytic virus | Pending | 07-Sep-2022 | ||
| EP-4585220-A1 | Novel use of oncolytic virus | Pending | 07-Sep-2022 | ||
| EP-4585220-A4 | Novel use of oncolytic virus | Pending | 07-Sep-2022 | ||
| US-20260091070-A1 | Novel use of oncolytic virus | Pending | 07-Sep-2022 | ||
| WO-2024054040-A1 | Novel use of oncolytic virus | Inactive | 07-Sep-2022 | A61K35/768 |
SillaJen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SillaJen Investments & Acquisitions (3)
SillaJen’s most recent deal was a Merger/Acquisition with Woosung Pharma. The deal was made on 13-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Woosung Pharma | 13-Mar-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Crossfire Oncology (BAL0891) | 20-Sep-2022 | Corporate Asset Purchase | Drug Discovery | ||
| Jennerex Biotherapeutics | 18-Mar-2014 | Merger/Acquisition | Drug Discovery |
SillaJen ESG
Risk Overview
Risk Rating
Updated September, 30, 2023
30.82 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,111
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
SillaJen Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Woosung Pharma | Suwon, South Korea | 2015 |
SillaJen FAQs
-
When was SillaJen founded?
SillaJen was founded in 2006.
-
Where is SillaJen headquartered?
SillaJen is headquartered in Seoul, South Korea.
-
What is the size of SillaJen?
SillaJen has 49 total employees.
-
What industry is SillaJen in?
SillaJen’s primary industry is Drug Discovery.
-
Is SillaJen a private or public company?
SillaJen is a Public company.
-
What is SillaJen’s stock symbol?
The ticker symbol for SillaJen is 215600.
-
What is the current stock price of SillaJen?
As of 13-Nov-2026 the stock price of SillaJen is $1.42.
-
What is the current market cap of SillaJen?
The current market capitalization of SillaJen is $197M.
-
What is SillaJen’s current revenue?
The trailing twelve month revenue for SillaJen is $7.42M.
-
Who are SillaJen’s competitors?
Iovance Biotherapeutics, NextCure, Marker Therapeutics, Sorrento Therapeutics, and Fate Therapeutics are some of the 68 competitors of SillaJen.
-
What is SillaJen’s annual earnings per share (EPS)?
SillaJen’s EPS for 12 months was -$0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
